WALTHAM, Mass. , Nov. 07, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will present at the Jefferies London
Minerva management to provide update on Phase 3 clinical trial with roluperidone and single-dose escalation study findings Additional topics to include review of recent BDNF data with roluperidone and KOL discussion of trans-diagnostic approach to treating negative symptoms in CNS/psychiatry
Findings suggest expanded therapeutic window and significantly improved cardiovascular safety margin compared to formulation used in Phase 2b trial All doses tested up to 256 milligrams appear safe and well tolerated with no significant changes in cardiac repolarization and QTc intervals Tested
WALTHAM, Mass. , Nov. 21, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will present at the Evercore ISI
WALTHAM, Mass. , Nov. 28, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the filing of a U.S.
Management to host conference call WALTHAM, Mass. , March 05, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release
Recruitment active in five late-stage trials with three compounds directed toward significant unmet medical needs Target indications include schizophrenia, major depressive disorder and insomnia disorder Five key data readouts expected in 2019 Management to host conference call today at 8:30 a.m.
Decision Resources Group to provide review of the disease landscape and forecast Key opinion leader to discuss negative symptoms in schizophrenia Minerva to outline roluperidone’s potential position within the disease landscape WALTHAM, Mass. , March 18, 2019 (GLOBE NEWSWIRE) -- Minerva
Findings show roluperidone increases release and gene expression of BDNF, as well as release of GDNF Data presented at 2019 Congress of the Schizophrenia International Research Society WALTHAM, Mass. , April 11, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc.
Management to host conference call WALTHAM, Mass. , April 29, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release